Literature DB >> 7789481

Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus.

J M Zahm1, S Girod de Bentzmann, E Deneuville, C Perrot-Minnot, A Dabadie, F Pennaforte, M Roussey, S Shak, E Puchelle.   

Abstract

Recombinant human deoxyribonuclease (rhDNase) has been demonstrated to reduce the viscosity of purulent cystic fibrosis (CF) respiratory mucus, to improve pulmonary function and to reduce the risk of respiratory tract infectious exacerbations, but its effect on mucus transportability has not so far been investigated. The dose-dependent effect of rhDNase was analysed in vitro on mucus transport rate (tr) by ciliary activity and by simulated cough (cough transport (ct)), as well as on mucus viscosity and surface properties. Purulent CF sputa (n = 15) were incubated for 30 min at 37 degrees C with either rhDNase at three different concentrations (final concentrations 0.2, 2 or 20 micrograms.ml-1 of mucus) or placebo. No significant dose-dependent effect of rhDNase on the mucociliary transport rate was observed when the samples wer statistically analysed together. However, in the larger group of mucus samples (n = 11) with a low initial mucociliary transport rate, the latter was improved at each rhDNase concentration (tr0.2 = 0.69, tr2 = 0.88 and tr20 = 0.87) as compared to placebo (trp = 0.58). In the smaller group of mucus samples (n = 4) with high initial transport rate, a decrease in mucociliary transport rate was observed, particularly at the highest concentration rhDNase assayed, i.e. 20 micrograms.ml-1 of mucus (tr20 = 0.58) as compared to placebo (trp = 0.86). The mucus cough transport was increased by rhDNase (ct0.2 = 25 mm, ct2 = 27.5 mm and ct20 = 31 mm) as compared to placebo (ctp = 23.5 mm).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7789481     DOI: 10.1183/09031936.95.08030381

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

1.  Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha.

Authors:  F Ratjen; C-M Hartog; K Paul; J Wermelt; J Braun
Journal:  Thorax       Date:  2002-11       Impact factor: 9.139

Review 2.  The role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, more problems.

Authors:  M S Zach
Journal:  Thorax       Date:  1996-07       Impact factor: 9.139

3.  Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis.

Authors:  N N Sanders; H Franckx; K De Boeck; J Haustraete; S C De Smedt; J Demeester
Journal:  Thorax       Date:  2006-11       Impact factor: 9.139

4.  Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.

Authors:  Yan Yang; Michael D Tsifansky; Chia-Jung Wu; Hae In Yang; Gudrun Schmidt; Yoon Yeo
Journal:  Pharm Res       Date:  2009-10-22       Impact factor: 4.200

Review 5.  Mucin gene expression in rhinitis syndromes.

Authors:  Asunción Martínez-Antón; Jordi Roca-Ferrer; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2006-05       Impact factor: 4.919

6.  Transport of particles in intestinal mucus under simulated infant and adult physiological conditions: impact of mucus structure and extracellular DNA.

Authors:  Adam Macierzanka; Alan R Mackie; Balazs H Bajka; Neil M Rigby; Françoise Nau; Didier Dupont
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

7.  Reassessment of the importance of mucins in determining sputum properties in cystic fibrosis.

Authors:  Alex Horsley; Karine Rousseau; Caroline Ridley; William Flight; Andrew Jones; Thomas A Waigh; David J Thornton
Journal:  J Cyst Fibros       Date:  2013-12-12       Impact factor: 5.482

8.  Rheological analysis of sputum from patients with chronic bronchial diseases.

Authors:  Jérémy Patarin; Étienne Ghiringhelli; Guillaume Darsy; Martinien Obamba; Philippe Bochu; Boubou Camara; Sébastien Quétant; Jean-Luc Cracowski; Claire Cracowski; Matthieu Robert de Saint Vincent
Journal:  Sci Rep       Date:  2020-09-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.